Mark T Esser Selected Research

Mark T Esser Research Topics

Disease

23	Infections 01/2023 - 01/2003
14	COVID-19 05/2024 - 01/2022
5	Respiratory Syncytial Virus Infections 04/2024 - 01/2013
5	Uterine Cervical Dysplasia 03/2008 - 04/2005
4	Respiratory Tract Infections (Respiratory Tract Infection) 01/2020 - 01/2013
3	Genital Diseases 03/2008 - 05/2005
3	Papillomavirus Infections 03/2008 - 05/2005
3	Condylomata Acuminata (Genital Wart) 05/2007 - 05/2005
3	Uterine Cervical Neoplasms (Cancer of the Cervix) 03/2007 - 04/2005
2	Human Influenza (Influenza) 07/2023 - 01/2003
2	Pneumonia (Pneumonitis) 11/2022 - 01/2021
2	Healthcare-Associated Pneumonia 11/2022 - 08/2016
2	Disease Progression 10/2022 - 01/2019
2	Bacteremia 01/2019 - 01/2015
2	Neoplasms (Cancer) 05/2007 - 01/2003
1	Severe Acute Respiratory Syndrome 05/2024
1	Body Weight (Weight, Body) 03/2024
1	Squamous Cell Carcinoma of Head and Neck 01/2023
1	Lung Diseases (Lung Disease) 01/2021
1	Ventilator-Associated Pneumonia 01/2021
1	Chronic Disease (Chronic Diseases) 01/2021
1	Fever (Fevers) 01/2019
1	Liver Diseases (Liver Disease) 01/2019
1	HIV Infections (HIV Infection) 01/2019
1	Chronic Obstructive Pulmonary Disease (COPD) 01/2019
1	Coinfection 01/2019
1	Hemolysis 01/2015
1	Adenocarcinoma in Situ 05/2007
1	Persistent Infection 05/2005
1	Malaria 01/2003

Drug/Important Bio-Agent (IBA)

20	VaccinesIBA 01/2023 - 01/2003
12	Monoclonal AntibodiesIBA 02/2024 - 08/2016
10	AntibodiesIBA 04/2024 - 03/2008
9	cilgavimab and tixagevimab drug combinationIBA 05/2024 - 01/2022
8	tixagevimabIBA 05/2024 - 01/2022
8	cilgavimabIBA 05/2024 - 01/2022
5	Immunoglobulin G (IgG)IBA 01/2019 - 05/2009
5	Papillomavirus Vaccines (HPV Vaccines)IBA 10/2010 - 01/2003
4	Proteins (Proteins, Gene)FDA Link 07/2023 - 05/2009
3	nirsevimabIBA 04/2024 - 01/2020
3	Neutralizing AntibodiesIBA 12/2023 - 01/2015
3	EnzymesIBA 01/2015 - 01/2013
2	DNA (Deoxyribonucleic Acid)IBA 01/2024 - 01/2008
2	gremubamabIBA 11/2022 - 08/2016
2	AntigensIBA 10/2022 - 01/2016
2	Anti-Bacterial Agents (Antibiotics)IBA 01/2021 - 01/2019
2	suvratoxumabIBA 01/2021 - 08/2016
2	CytokinesIBA 01/2019 - 01/2003
2	Palivizumab FDA Link 12/2017 - 01/2017
2	Virus-Like Particle VaccinesIBA 03/2008 - 10/2007
1	A-Form DNA (A-DNA)IBA 01/2023
1	Interleukin-12 (IL 12)IBA 01/2023
1	MEDI0457IBA 01/2023
1	durvalumabIBA 01/2023
1	Immune Checkpoint InhibitorsIBA 01/2023
1	Glycoproteins (Glycoprotein)IBA 10/2022
1	RNA-Directed DNA Polymerase (Reverse Transcriptase)IBA 01/2022
1	N-(2-cyanoethylene)urea (BA 1)IBA 01/2022
1	N-methyl-valyl-amiclenomycin (BA 2)IBA 01/2022
1	Interleukin-6 (Interleukin 6)IBA 01/2019
1	GoldIBA 01/2019
1	Immunoglobulin M (IgM)IBA 01/2019
1	Interleukin-2 (IL2)IBA 01/2019
1	Biomarkers (Surrogate Marker)IBA 01/2019
1	Interleukin-4 (Interleukin 4)IBA 01/2019
1	Interleukin-7 (Interleukin 7)IBA 01/2019
1	Granulocyte-Macrophage Colony-Stimulating Factor (GM-CSF)IBA 01/2019
1	Interleukin-8 (Interleukin 8)IBA 01/2019
1	Interleukin-10 (Interleukin 10)IBA 01/2019
1	ImmunosorbentsIBA 01/2015
1	MEDI-559IBA 01/2013
1	IronIBA 05/2009
1	mannosyl(9)-N-acetylglucosamine(2)IBA 10/2008
1	EpitopesIBA 10/2008
1	Synthetic Vaccines (Recombinant Vaccines)IBA 10/2008
1	asoxime chloride (H16)IBA 03/2008
1	Combined VaccinesIBA 05/2005
1	Viral ProteinsIBA 04/2005
1	AluminumIBA 04/2005

Therapy/Procedure

5	Therapeutics 03/2024 - 01/2019
1	Intramuscular Injections 01/2023
1	Aftercare (After-Treatment) 01/2021
1	Artificial Respiration (Mechanical Ventilation) 01/2021
1	Immunotherapy 01/2019
1	Renal Dialysis (Hemodialysis) 01/2015
1	Injections 03/2008